Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K FilingGlobeNewsWire • 04/19/24
Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024GlobeNewsWire • 04/18/24
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial ProductsGlobeNewsWire • 04/15/24
Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental CellsGlobeNewsWire • 04/08/24
Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3LGlobeNewsWire • 03/26/24
Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular DystrophyGlobeNewsWire • 03/20/24
Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE SummitGlobeNewsWire • 03/14/24
Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World CongressGlobeNewsWire • 03/12/24
Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental CellsGlobeNewsWire • 03/07/24
Celularity's Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface DiseaseGlobeNewsWire • 02/14/24
Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development PipelineGlobeNewsWire • 02/01/24
Celularity and Genting Leaders Comments on Closing $21 Million Financing TransactionsGlobeNewsWire • 01/25/24
Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral HealthcareGlobeNewsWire • 01/04/24
Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023GlobeNewsWire • 01/03/24
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q FilingGlobeNewsWire • 11/24/23
Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product ClassificationGlobeNewsWire • 10/18/23
Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of DirectorsGlobeNewsWire • 09/07/23
Celularity Announces Multi-Year Research Collaboration Services Agreement With RegeneronGlobeNewsWire • 08/29/23
Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic ApplicationsGlobeNewsWire • 07/27/23
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Celularity Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsPRNewsWire • 07/19/23
Celularity Human Placental-Derived Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in StudiesGlobeNewsWire • 07/18/23